PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

27 Jun 2017 11:48

RNS Number : 3051J
Circassia Pharmaceuticals Plc
27 June 2017
 

For filings with the FCA include the annex
 

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Circassia Pharmaceuticals Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Chase (GA Group) Nominees Limited 12,065,941*

 

HSBC Global Custody Nominee (UK) Limited 47,836*

 

State Street Nominees Limited 197,282*

 

* denotes direct interest

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

23 June 2017

6. Date on which issuer notified:

26 June 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

4% to 3% Change at Direct Interest Level (Box 8A)

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary SharesGB00BJVD3B28

16,516,463*

16,516,463*

12,311,059

12,311,059

Not Disclosable**

3.71%

Not Disclosable**

 

* Includes right to recall loaned shares (2,004,649)

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

3,457,526*

 

*Direct interest

1.04%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

15,768,585

4.75%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

Figures are based on a total number of voting rights of 332,244,588 as per the Company's Total Voting Rights Update Announcement of 12 April 2017.

 

** Although not reportable, as per DTR5.1.5,the non-disclosable (indirect) position is currently 717,718 shares, and is included here in the interests of transparency.

 

14. Contact name:

Julien Cotta

15. Contact telephone number:

01865 405560

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFRMMTMBITBBR
Date   Source Headline
18th Jan 20192:22 pmRNSBlock listing Interim Review
4th Jan 20191:48 pmRNSResult of General Meeting
4th Jan 20197:00 amRNSGeneral Meeting Business Update
31st Dec 20187:00 amRNSTotal Voting Rights
27th Dec 20187:00 amRNSHolding(s) in Company
17th Dec 20187:00 amRNSListing Rule 9.6.14(R) Disclosure
11th Dec 201812:10 pmRNSOption exercised for Tudorza from AstraZeneca
10th Dec 20185:59 pmRNSPosting of Shareholder Circular
10th Dec 201812:59 pmRNSProposed admission to trading on AIM
30th Nov 20187:00 amRNSTotal Voting Rights
31st Oct 20182:13 pmRNSTotal Voting Rights
25th Oct 20183:00 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSTotal Voting Rights
27th Sep 20187:00 amRNSInterim Results for Six Months Ended 30 June 2018
7th Sep 201811:36 amRNSNotice of Interim Results and Broker Appointment
3rd Sep 201812:15 pmRNSTotal Voting Rights
16th Aug 20184:25 pmRNSDirector Declaration
13th Aug 20187:00 amRNSRegulatory Application
31st Jul 20187:00 amRNSTotal Voting Rights
18th Jul 20184:14 pmRNSHolding(s) in Company
18th Jul 20184:12 pmRNSHolding(s) in Company
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 20181:52 pmRNSIssue of Equity and Total Voting Rights
16th Jul 20183:28 pmRNSResult of AGM
2nd Jul 20187:00 amRNSBlock listing Interim Review
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 201812:23 pmRNSPublication of Circular
11th Jun 20184:20 pmRNSHolding(s) in Company
4th Jun 20184:18 pmRNSDirector/PDMR Shareholding
4th Jun 20184:15 pmRNSDirector/PDMR Shareholding
4th Jun 20184:14 pmRNSDirector/PDMR Shareholding
1st Jun 20187:00 amRNSUS Filing of Duaklir NDA & Tudorza Supplement NDA
31st May 20187:00 amRNSTotal Voting Rights
30th May 201812:05 pmRNSResult of AGM
22nd May 20187:00 amRNSPositive Data Presented at 2018 ATS Conference
18th May 201810:57 amRNSBlock listing Interim Review
14th May 20183:37 pmRNSHolding(s) in Company
30th Apr 20185:08 pmRNSTotal Voting Rights Update
27th Apr 20184:45 pmRNSAnnual Financial Report and Notice of AGM
26th Apr 20185:46 pmRNSHolding(s) in Company
26th Apr 20185:46 pmRNSHolding(s) in Company
24th Apr 20187:00 amRNSFinal Results
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
12th Apr 20187:00 amRNSNotice of Results
29th Mar 20187:00 amRNSTotal Voting Rights
16th Mar 20184:40 pmRNSSecond Price Monitoring Extn
16th Mar 20184:35 pmRNSPrice Monitoring Extension
28th Feb 20182:01 pmRNSTotal Voting Rights
13th Feb 20187:00 amRNSDirectorate Change
8th Feb 20187:00 amRNSReceives Innovative Tech Contract from Vizient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.